Comparative effects of flaxseed oil and vitamin E on non-invasive markers of liver in patients with nonalcoholic fatty liver disease.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013111715427N1

Enrollment

Registered

2014-01-21

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver. Nonalcoholic fatty liver disease

Interventions

Intervention 1: Intervention group: Oral Flaxseed every day 3 times (1 gr) for 2 months. Intervention 2: Control group: E Vitamin, Oral capsule, 3 times a day for 2 months.

Treatment - Drugs

Intervention group: Oral Flaxseed every day 3 times (1 gr) for 2 months

Control group: E Vitamin, Oral capsule, 3 times a day for 2 months

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: The major inclusion criteria are: The enzyme Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at least 1.5 times above the normal limit, confirmed by the kidney sonography; Meeting at least one of the following criteria: Within the age range of 15-60 years old, diabetes, Hyperlipidemia, and Obesity. The major exclusion criteria are as follows: Consuming alcohol or having a history of drinking problems; Positive serology for viral hepatitis (C , B); Positive Anti-Nuclear Antibody (ANA) or Anti-Mitochondrial Antibodies (AMA) tests, Alpha-1 antitrypsin; Reduced serum levels of ceruloplasmin or increasing levels of Anti-smooth muscle (ASMA) and Liver kidney microsomal type 1 antibody (LKM1) antibodies; Ferritin level larger than 450, or Iron and Total iron binding capacity IRON/TIBC less than 45%; The patients being diagnosed with acute or chronic illnesses which cause disorders in LFT (liver function tests), before or during the medical intervention; the patients’ consumption of drugs, before or during the medical intervention, which cause disorders in LFT; Pregnancy; Age less than 15 or above 60 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver Enzyme. Timepoint: Admission and 2 months after applying the intervention. Method of measurement: Blood Sampling.	—

Secondary

Measure	Time frame
Blood Glucose. Timepoint: Admission and 2 months after applying the intervention. Method of measurement: Blood Sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Beheshti Namdar

Imam Reza Hospital

minavi_nami@yahoo.com+98 51 1843 4637

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026